Literature DB >> 7561610

Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action.

H Yamamoto1, L J Murphy.   

Abstract

We recently identified and characterized a protease present in rat serum which is capable of generating des(1-3)IGF-I. In this study, we have investigated the effects of GH deficiency and replacement on the activity of this protease in rat serum and tissue extracts. Protease activity was significantly higher in sera from hypophysectomized (hypox) rats than sham-operated rats (P < 0.001) and GH treatment of hypox rats (human GH, 100 micrograms/100 g body weight i.p. for 10 days) significantly reduced the levels towards normal. The addition of IGF-I to hypox rat serum to achieve IGF-I concentrations comparable with or greater than that seen in normal rat serum had no effect on the measured protease activity. Protease activity was also detected in tissue extracts. The level of protease activity in the various tissues from sham-operated rats demonstrated the following order: liver > testes > heart > skeletal muscle > lung > thymus > kidney > brain > spleen. In all tissue extracts examined, except that from the lung, the levels of protease activity were higher in extracts from hypox rats compared with sham-operated rats. The largest differences between tissue extracts from hypox and sham-operated rats were seen in spleen (4-fold higher), kidney (2.27-fold), testes (1.55-fold) and heart (1.31-fold). In the liver, kidney and testes, GH treatment significantly reduced protease activity. Since the pattern of serum IGF-binding proteins (IGFBPs) differ in hypox rats compared with normal rats, we determined whether these changes could result in enhanced serum binding of des(1-3)IGF-I.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561610     DOI: 10.1677/joe.0.1460141

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  21 in total

1.  Post-transcriptional regulation of IGF1R by key microRNAs in long-lived mutant mice.

Authors:  Ruqiang Liang; Amit Khanna; Senthilkumar Muthusamy; Na Li; Harshini Sarojini; John J Kopchick; Michal M Masternak; Andrzej Bartke; Eugenia Wang
Journal:  Aging Cell       Date:  2011-12       Impact factor: 9.304

Review 2.  Neurodevelopmental effects of insulin-like growth factor signaling.

Authors:  John O'Kusky; Ping Ye
Journal:  Front Neuroendocrinol       Date:  2012-06-16       Impact factor: 8.606

Review 3.  Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit?

Authors:  Luigi Puglielli
Journal:  Neurobiol Aging       Date:  2007-02-20       Impact factor: 4.673

4.  Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties.

Authors:  Vladislava Paharkova-Vatchkova; Kuk-Wha Lee
Journal:  Endocr Relat Cancer       Date:  2010-03-08       Impact factor: 5.678

5.  Stability of local brain levels of insulin-like growth factor-I in two well-characterized models of decreased plasma IGF-I.

Authors:  Michelle M Adams; M Elizabeth Forbes; M Constance Linville; David R Riddle; William E Sonntag; Judy K Brunso-Bechtold
Journal:  Growth Factors       Date:  2009-06       Impact factor: 2.511

Review 6.  IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions.

Authors:  Jian Guan; Peter D Gluckman
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

7.  Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model.

Authors:  Edoardo Parrella; Tom Maxim; Francesca Maialetti; Lu Zhang; Junxiang Wan; Min Wei; Pinchas Cohen; Luigi Fontana; Valter D Longo
Journal:  Aging Cell       Date:  2013-03-11       Impact factor: 9.304

8.  The IGF-derived tripeptide Gly-Pro-Glu is a weak NMDA receptor agonist.

Authors:  Christopher E Vaaga; Kenneth R Tovar; Gary L Westbrook
Journal:  J Neurophysiol       Date:  2014-06-18       Impact factor: 2.714

9.  Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle.

Authors:  M Li; C Li; W S Parkhouse
Journal:  Mol Cell Biochem       Date:  2002-07       Impact factor: 3.396

10.  NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats.

Authors:  Hans H Wei; Xi-Chun M Lu; Deborah A Shear; Anu Waghray; Changping Yao; Frank C Tortella; Jitendra R Dave
Journal:  J Neuroinflammation       Date:  2009-08-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.